期刊文献+

低分子肝素钙联合酚妥拉明治疗肺源性心脏病急性加重期的效果 被引量:11

The effect of combination of low molecular weight heparin calcium and phentolamine on patients with acute exacerbation of pulmonary heart disease
下载PDF
导出
摘要 目的探究低分子肝素钙联合酚妥拉明对肺心病急性加重期患者的治疗效果。方法选取肺心病急性加重期患者80例,按照随机数字表法分为观察组(40例)和对照组(40例)。两组患者均采取常规治疗,观察组患者在此基础上联合低分子肝素钙与酚妥拉明治疗,对照组则单独应用酚妥拉明。比较两组患者的治疗效果、血气分析及肺功能的变化情况。结果观察组治疗总有效率为90.0%高于对照组的72.5%;两组患者治疗后的血气分析指标均有不同程度的改善,但观察组患者血氧分压(PaO_2)高于对照组,二氧化碳分压(PaCO_2)低于对照组;治疗后两组患者第一秒用力呼气容积占预计值百分比(FEV1%)及第一秒用力呼气容积/用力肺活量(FEV1/FVC)均增加,但观察组高与对照组患者。两组以上指标比较,差异有统计学意义(P<0.05)。结论常规治疗与低分子肝素钙和酚妥拉明结合治疗肺心病急性加重期患者不仅可以提高疗效,还能提高PaO_2、FEV1%及FEV1/FVC,降低Pa CO2含量,改善患者肺功能。 Objective To explore the therapeutic effect of low molecular weight heparin calcium combined with phentolamine on patients with acute exacerbation of chronic pulmonary heart disease. Methods Eighty patients with acute exacerbation of chronic pulmonary heart disease were selected and randomly divided into observation group (40 cases) and control group (40 cases).All patients had received routine treatment.The patients of observation group were treated with low molecular heparin calcium combined with phentolamine,while the control group was treated with phentolamine alone on the basis of routine treatment.The treatment effect,blood gas analysis and the change of lung function were compared between the two groups were compared. Results The totally effective rate of observation group was significantly better than that of the control group (90.0% vs 72.5%).The indexes of blood gas analysis were improved in different degree after treatment in two groups,but the PaO 2 of observation group was higher than the control group,PaCO 2 was lower than the control group.The FEV 1% and FEV 1/FVC of two groups were increased after treatment,but the observation group was higher than the control group,differences were statistically significant( P〈 0.05). Conclusion Conventional therapy combined with low-molecular-weight heparin and phentolamine in the treatment of patients with acute exacerbation of chronic pulmonary heart disease can not only improve therapeutic effect,but also improve PaO 2,FEV 1%,FEV 1/FVC,and lung function.
作者 王能兵 池琼 刘家兴 蒋永刚 付瑜 杨义健 Wang Nengbing;Chi Qiong;Liu Jiaxing;Jiang Yonggang;Fu Yu;Yang Yijian(Department of Respiratory,Yiwu City Fuyuan Hospital,Yiwu 322000,China)
出处 《中国临床保健杂志》 CAS 2018年第3期374-376,共3页 Chinese Journal of Clinical Healthcare
关键词 肺心病 肝素低分子量 酚妥拉明 Pulmonary heart disease;Heparin,low-molecular-weight Phentolamine
  • 相关文献

参考文献16

二级参考文献132

共引文献145

同被引文献105

引证文献11

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部